Paraquin (dihydroartemisinin + piperaquine phosphate): Uses, Dosage & Side Effects

What it's for (Indications)

Dihydroartemisinin + piperaquine phosphate is primarily indicated for the treatment of uncomplicated *Plasmodium falciparum* malaria in adults, children, and infants weighing 5 kg or more.
It is a fixed-dose combination therapy designed to provide effective and rapid clearance of parasites, particularly in regions where resistance to other antimalarial drugs is prevalent.
This combination is crucial in combating drug-resistant strains of *P.
falciparum*.
While its primary role is in *P.
falciparum*, it may also be effective against *Plasmodium vivax* malaria, though further treatment with an anti-relapse drug like primaquine is typically required to address hypnozoites and prevent recurrent *P.
vivax* episodes.
It is not indicated for the prophylaxis of malaria or for the treatment of severe malaria, which requires parenteral therapy and close medical supervision.

Dosage Information

Type	Guideline
Standard	The dosage of dihydroartemisinin + piperaquine phosphate is administered orally once daily for three consecutive days, with the dose determined by body weight. For adults and children weighing 36 kg or more, the typical regimen is three tablets (each containing 40 mg dihydroartemisinin and 320 mg piperaquine phosphate) taken once daily for three days. For children weighing between 5 kg and 35 kg, specific pediatric formulations or dose adjustments based on weight bands are used, ensuring appropriate mg/kg dosing. It is crucial to administer the medication with food or a fatty meal to enhance absorption, and patients should be advised to take the full prescribed course, even if symptoms improve, to ensure complete parasite clearance and minimize the risk of developing drug resistance. Non-adherence can lead to treatment failure and contribute to the emergence of resistant strains. Healthcare providers must ensure accurate weight-based dosing, especially in pediatric populations, and provide clear instructions for administration.

Type

Guideline

Standard

The dosage of dihydroartemisinin + piperaquine phosphate is administered orally once daily for three consecutive days, with the dose determined by body weight. For adults and children weighing 36 kg or more, the typical regimen is three tablets (each containing 40 mg dihydroartemisinin and 320 mg piperaquine phosphate) taken once daily for three days. For children weighing between 5 kg and 35 kg, specific pediatric formulations or dose adjustments based on weight bands are used, ensuring appropriate mg/kg dosing. It is crucial to administer the medication with food or a fatty meal to enhance absorption, and patients should be advised to take the full prescribed course, even if symptoms improve, to ensure complete parasite clearance and minimize the risk of developing drug resistance. Non-adherence can lead to treatment failure and contribute to the emergence of resistant strains. Healthcare providers must ensure accurate weight-based dosing, especially in pediatric populations, and provide clear instructions for administration.

Safety & Warnings

Common Side Effects

Common side effects associated with dihydroartemisinin + piperaquine phosphate are generally mild to moderate and often transient.
These include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea.
Other frequently reported adverse events encompass headache, dizziness, fatigue, loss of appetite (anorexia), cough, and weakness.
More serious, albeit less common, side effects primarily involve cardiovascular effects due to piperaquine's propensity to prolong the QT interval on an electrocardiogram.
This risk necessitates careful consideration in patients with pre-existing cardiac conditions or those on other QT-prolonging medications.
Rarely, hypersensitivity reactions, liver enzyme elevations, and skin rashes may occur.
Patients should be advised to seek medical attention if they experience severe or persistent side effects, particularly palpitations, syncope, or severe abdominal pain, as these could indicate a more serious underlying issue.

Serious Warnings

Black Box Warning: None
While dihydroartemisinin + piperaquine phosphate does not carry an FDA Black Box Warning, several serious warnings and precautions are paramount for safe and effective use.
The most significant concern is the potential for dose-dependent QT interval prolongation due to piperaquine.
This can increase the risk of serious ventricular arrhythmias, including Torsades de Pointes, which can be fatal.
Therefore, this drug is contraindicated in patients with a history of QTc prolongation, congenital long QT syndrome, significant cardiac arrhythmias, or uncontrolled heart failure.
Caution is advised when prescribing to patients with uncorrected hypokalemia or hypomagnesemia, and concurrent use with other QT-prolonging medications should be avoided.
Electrocardiogram (ECG) monitoring is recommended in high-risk patients or those with multiple cardiac risk factors.
This combination is not for the treatment of severe malaria or for malaria prophylaxis.
Patients should be counseled on the importance of completing the full course of treatment to prevent recrudescence and the development of drug resistance.
Use in pregnant or breastfeeding women should only occur after careful assessment of the benefit-risk ratio, given limited data and the potential for fetal/infant exposure.

How it Works (Mechanism of Action)

The therapeutic efficacy of dihydroartemisinin + piperaquine phosphate stems from the synergistic action of its two distinct antimalarial components, targeting different aspects of the parasite's life cycle within red blood cells. Dihydroartemisinin (DHA) is a potent, rapid-acting artemisinin derivative that primarily targets the asexual blood stages of *Plasmodium* parasites. Its mechanism involves the interaction of its endoperoxide bridge with intraparasitic heme, leading to the formation of highly reactive free radicals and alkylating agents. These agents inflict oxidative stress and damage to crucial parasite proteins, enzymes, and membranes, thereby rapidly clearing parasitemia and alleviating acute symptoms. Piperaquine (PQ) is a bisquinoline derivative that acts as a slower-acting, long-half-life partner drug. Its primary mechanism involves accumulating within the parasite's acidic food vacuole, where it interferes with the detoxification of heme (the by-product of hemoglobin digestion). By inhibiting heme polymerization, piperaquine leads to the accumulation of toxic free heme within the parasite, ultimately causing parasite death. The combination leverages DHA's rapid onset of action for quick symptom resolution and PQ's long half-life to provide sustained antimalarial activity, preventing recrudescence and reducing the selection pressure for resistance to either drug alone.